Retrospective Analysis of Guillain-Barré Syndrome: A Pharmaceutical Perspective

One of the most common causes of flaccid paralysis, Guillain Barre Syndrome (GBS) has long been a major health problem around the world. Substantial evidence supports the autoimmune nature of this syndrome, with the autoantibody profile playing a crucial role in confirming the clinical and electrophysiological associations between GBS and various other peripheral nerve disorders. This research is aimed to assess the clinical features, electrophysiological, treatment pattern and functional outcome of a multi-centre cohort of GBS patients. Tertiary care hospitals in the Maharashtra region of India were the focus of the present retrospective observational cohort study. Data for the GBS cases admitted during June 2018 to Dec 2023 were included for the current study. Data collected were included clinical features, reported electrophysiological data, treatment and outcome. All the data were assessed with the help of statistical models. The study comprised a total of 25 participants diagnosed with GBS. Males made up the vast majority of the GBS patients (72%). An average age at presentation was 44 ±13 years. The symptom that present most frequently was ascending or upward paralysis that happened in 20 patients (80%). The remaining common symptoms were sensory disturbances (40%), bladder and bowel complaints (28%) and difficulty in up-squatting. In this cohort analysis, COVID-19 infection was the most common antecedent event (44%). All the patients administered GBS-specific therapy of whom 84 % patients had given Intravenous Immunoglobulin (IVIG) along with Antibiotics, 12% of patients had given Plasmapheresis treatment along with IVIG and 4% of patients had given IVIG, Antibiotics, Plasmapheresis and ventilator. According to this research the maximum number of patients had a favourable functional outcome, i.e. 92% and 8% patients showed poor functional outcome.